Avenue Therapeutics, Inc.
ATXI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.00 | 10.61 |
| FCF Yield | -34.84% | -731.61% | -299.68% | -0.32% |
| EV / EBITDA | -2.07 | -0.02 | 1.16 | 164,799.50 |
| Quality | ||||
| ROIC | -607.92% | -2,016.64% | -236.35% | -108.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.91 | 2.11 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 27.51% | -63.92% | -102.56% | 33.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | -0.44 | 1.86 | -537.57 |
| Interest Coverage | 0.00 | 0.00 | -6.93 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |